Table 3.

Univariate and multivariate analyses for prognostic factors of AC benefit through the transformation model

Prognostic factors	Univariate analyses				Multivariate analyses
	OS		PFS		OS		PFS
	P	HR (95.0% CI)	P	HR (95.0% CI)	P	HR (95.0% CI)	P	HR(95.0% CI)
Gender Male/female	0.059	2.786 (0.962–8.068)	0.069	3.374 (0.908–12.538)	0.251	2.071 (0.598–7.174)	0.204	2.513 (0.606–10.421)
Age < 60/ ≥ 60	0.820	0.909 (0.401–2.063)	0.873	0.932 (0.392–2.213)
ECOG Scoring 0/1–2	0.249	0.624 (0.280–1.391)	0.743	1.151 (0.497–2.666)
Tumor location Up/down	0.115	0.520 (0.231–1.173)	0.212	0.585 (0.253–1.356)
Clinical stage II–III/IV	0.001	0.208 (0.082–0.531)	0.102	0.485 (0.204–1.156)	1.000
T stage T2-3/T4	0.139	0.423 (0.135–1.324)	0.050	0.335 (0.112–1.001)			0.064	0.304 (0.086–1.070)
N stage N0-1/N2-3	0.002	0.240 (0.097–0.596)	0.141	0.523 (0.221–1.240)	1.000
Radiation dose < 59.4 Gy/ ≥ 59.4 Gy	0.444	1.438 (0.568–3.641)	0.177	1.913 (0.746–4.903)
MacroType Fungating + Ulcer/Medulla + Constrictive	0.129	0.538 (0.242–1.197)	0.004	0.280 (0.116–0.673)			0.005	0.246 (0.092–0.661)
CT Regimen PF/TP	0.893	0.947 (0.428–2.093)	0.962	1.020 (0.443–2.352)
Target Delineation ENI/IFI	0.922	1.040 (0.473–2.288)	0.726	1.160 (0.506–2.662)
Short-term response Good/poor	< 0.001	5.500 (2.305–13.126)	< 0.001	5.029 (2.039–12.399)	< 0.001	5.969 (2.258–15.776)	0.003	4.395 (1.650–11.710)